Innovation

Innovation

Innovation

AI Pharma, data-enabled quality analysis, and digital operating tools for modern pharmaceutical capability.

At ViengKham, innovation is not a slogan; it is a way of building capability. We combine AI, structured data, and proven GMP discipline to make every batch more traceable, every decision better informed, and every document consistent. Our philosophy is simple: technology should earn its place by improving real outcomes for patients, partners, and regulators. We start from concrete problems on the production floor and in the laboratory, validate each tool before it is trusted, and scale only what demonstrably works.

AI Pharma

AI Pharma

Using data and intelligent tools to support R&D collaboration, production management, quality analysis, and efficiency.

 Healthy Longevity

Healthy Longevity

Healthy lifespan, metabolic health, chronic inflammation, mitochondria, cellular senescence, immune modulation, and neuroprotection.

 Formulation Development

Formulation Development

Formulation development, prescription screening, process optimization, stability studies, and dosage form transformation.

 Digital GMP & Quality Intelligence

Digital GMP & Quality Intelligence

AI for production management, quality trend analysis, deviation data, stability data, and document systems.
Our Approach

How We Innovate

We innovate problem-first, not technology-first. Every initiative begins with a measurable pain point — a slow review, a hard-to-trace record, a recurring deviation — and is tested against real production and quality data before it is adopted. Nothing reaches daily use until it is validated, documented, and owned by a responsible team.

  • Problem-first, evidence-driven design
  • Validate before you trust
  • Scale only what proves its value
  • Human judgement stays in control
AI Pharma

Data-Driven Pharmaceutical Workflows

AI is applied where it can create measurable operational value: organizing knowledge, reducing repetitive work, improving review speed, and supporting consistent execution across R&D, manufacturing, quality, and regulatory teams.

  • Quality trend analysis
  • R&D information retrieval
  • Regulatory knowledge organization
  • Production and supply coordination
Data Foundation

Trusted Data as the Foundation

Intelligent systems are only as reliable as the data beneath them. We invest first in clean, structured, and ALCOA+ aligned records so that every analysis, dashboard, and decision rests on data that is attributable, legible, contemporaneous, original, and accurate.

  • Structured, machine-readable records
  • Data integrity by design (ALCOA+)
  • Single source of truth across functions
  • Audit-ready traceability
R&D

Research Collaboration

Structured data, searchable documents, and shared technical records help teams compare formulation information, supplier data, process notes, and development outcomes more efficiently — turning individual experience into shared institutional knowledge.

  • Technical document indexing
  • Process knowledge capture
  • Cross-functional review support
Quality Intelligence

Quality Data and Trend Visibility

Digital quality records help identify recurring issues, deviation patterns, and opportunities for preventive action before they become larger operational risks — shifting quality from reactive firefighting to proactive control.

  • Deviation trend review
  • CAPA follow-up visibility
  • Batch and laboratory record analysis
Operations

Digital Operating Discipline

Innovation is useful only when it improves execution. ViengKham uses digital tools to support planning, training, document control, and management review — so that good practice becomes everyday practice.

  • Training knowledge base
  • Document lifecycle support
  • Management dashboard direction
Roadmap

From Pilot to Standard Practice

We grow innovation in deliberate stages — pilot, validate, standardize, and continuously improve. Each capability we adopt is designed to be sustainable, auditable, and aligned with international regulatory expectations, so progress compounds instead of resetting.

  • Stage-gated pilots
  • Measured rollout
  • Continuous improvement loops
  • Aligned with global GMP standards

From Molecule to Medicine: Our End-to-End Drug Development Pathway

At ViengKham, innovation isn’t just about discovering new molecules—it’s about delivering safe, effective medicines to patients through a rigorous, end-to-end process that combines AI-powered efficiency with proven scientific validation and GMP discipline. Below is our structured workflow from initial molecular screening to final product launch, built on the core principles of problem-first design, evidence-based validation, and consistent execution.

1. Molecule Discovery & AI-Assisted Screening

Building on our existing AI pharmaceutical capabilities:

  • What we deliver: Identification of high-potential candidate molecules for target diseases via protein structure prediction, molecule-target binding analysis, and natural product active ingredient screening.
  • Our approach: We use private AI models trained on pharmaceutical literature, formulation data, and quality records to narrow down candidate ranges quickly—all computational results are verified by lab experiments before moving forward, no shortcuts.
  • Core rule: AI is a tool to speed up research, not replace science. Every candidate must pass experimental validation first.
2. Preclinical Research & Animal Testing

Translating candidates into testable therapies with robust safety and efficacy data:

  • What we cover: In vitro pharmacodynamic evaluation, ADME (absorption, distribution, metabolism, excretion) studies, acute and chronic toxicity testing in animal models, and efficacy verification for targeted indications.
  • Compliance: All preclinical work is conducted with GLP-certified partners, following international regulatory standards. All data is stored as structured, ALCOA+-compliant records to ensure full traceability for regulatory submission.
  • Key output: A complete preclinical package that supports Investigational New Drug (IND) application filing, with clear safety margins and preliminary efficacy evidence.
3. Process Development & GMP Scale-Up

Turning lab-scale formulations into scalable, compliant manufacturing processes:

  • What we do: Optimize formulation parameters, develop stable manufacturing workflows, and scale up from pilot batches to commercial production capacity using our 6,000 sqm GMP facility.
  • Digital integration: We use digital tools to record every process parameter, track deviations, and analyze quality trends with AI to proactively fix issues before they impact batch consistency.
  • Link to our mission: This stage connects our AI R&D to real-world manufacturing—our strength isn’t just algorithms, it’s the ability to turn promising molecules into reliably producible medicines.
4. Regulatory Submission & Clinical Trials

Testing safety and efficacy in humans under strict regulatory oversight:

  • Steps: Prepare and submit IND documentation with structured preclinical and CMC (Chemistry, Manufacturing, Controls) data; conduct Phase I (safety/tolerability), Phase II (dose-finding/efficacy), and Phase III (confirmatory efficacy/safety) clinical trials in partnership with certified clinical sites.
  • Quality support: Our digital quality management system tracks all trial deviations, CAPA follow-ups, and data integrity checks to ensure full GCP compliance, making the submission process smoother and more transparent.
  • Goal: Generate robust clinical evidence that meets global regulatory requirements for marketing approval.
5. Commercial Manufacturing & Product Launch

Delivering consistent, high-quality products to patients after approval:

  • Production: Manufacture commercial batches under full GMP conditions, with 100% batch testing and release certification; every batch has complete traceability from raw materials to finished product.
  • Consistency focus: Digital training systems, document lifecycle management, and automated dashboards ensure every team follows standardized procedures—this is where our core slogan “Consistency is Our Innovation” comes to life.
  • Post-launch commitment: We continue stability testing and collect real-world evidence to monitor product performance long-term, making continuous improvements to better serve patient needs.

Closing: Open Collaboration for Better Health Outcomes

This end-to-end pathway is designed to be open and collaborative—we partner with academic researchers, biotech firms, clinical institutions, and regulatory experts across each stage to combine strengths and accelerate access to innovative medicines. Based in Laos, we connect regional manufacturing capabilities with global AI and R&D resources to meet unmet health needs, focusing on chronic diseases, metabolic health, and longevity.

As always, our philosophy holds: AI makes drug R&D more efficient, and science makes results more reliable. Every step of this pipeline is built to earn trust through validation, not just claim innovation.